Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Attacking plasma cell dyscrasia in AL amyloidosis

Vaishali Sanchorawala • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Daratumumab Isatuximab

Vaishali Sanchorawala, MD Boston University School of Medicine, Boston, MA, provides an overview into research and current treatments of plasma cell dyscrasia in light chain amyloidosis (AL amyloidosis), speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Vaishali Sanchorawala

1:55
Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
1:55
Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
1:58
Safety of birtamimab in AL amyloidosis: pooled analysis from multiple studies
Vaishali Sanchorawala • 12 Dec 2023
9:53
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Ashutosh Wechalekar et al. • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals